Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy
Study Drug Administration:
If you are found to be eligible to take part in this study, you will begin taking the study
drugs in 28-day cycles. One time a week during Cycle 1, you will receive rituximab by vein.
During Cycle 2, you will not receive rituximab. During Cycles 3-12, you will receive
rituximab on Day 1 of Cycles 3-12. Your first dose of rituximab will be given over 6-8
hours. If you tolerate your first dose well, you may receive the next doses over 2-4 hours.
If the doctor thinks it is needed, the next doses may given over a longer time.
Starting on Day 9 of Cycle 1, you will begin taking lenalidomide by mouth 1 time a day.
The dose and schedule of lenalidomide may change depending on the side effects you may have.
You should swallow lenalidomide capsules whole with a glass (8 ounces) water at the same
time each day. Do not break, chew, or open the capsules. If you miss a dose of
lenalidomide, take it as soon as you remember on the same day. If you miss a dose, it
should NOT be made up on another day.
During Cycle 1 only, you will take allopurinol by mouth 1 time a day on Days 1-14 to lower
the risk of side effects.
One (1) time a week during the first 5 weeks, blood (about 1 tablespoon) will be drawn for
After the first 5 weeks, blood (about 1 tablespoon) will be drawn for routine tests every 2
weeks until the doctor thinks your dose of lenalidomide can stay the same. After that,
blood (about 1 tablespoon) will be drawn every 4 weeks for the rest of the study for routine
At the end of Cycles 3, 6, and 12, you will have a bone marrow biopsy and aspiration to
check the status of the disease.
If you stay on study past 12 cycles, once every 6 cycles (Cycles 18, 24, 30, and so on), you
will have a bone marrow biopsy and aspiration to check the status of the disease.
Blood (about 1 tablespoon) will be drawn more often if the dose of lenalidomide needs to be
changed or if you have intolerable side effects.
If you are able to become pregnant, you will have a urine or blood (less than 1 teaspoon)
pregnancy test 10-14 days and 24 hours before the first dose of lenalidomide, even if you
have not had a menstrual period due to treatment of the disease or had only 1 menstrual
period in the past 24 months.
If you have regular or no menstrual cycles, you will then have a urine or blood (less than 1
teaspoon) pregnancy test every week for the first 4 weeks, then every 4 weeks while taking
lenalidomide, again as soon as you stop taking lenalidomide, and then 28 days after you have
stopped taking lenalidomide.
If you have irregular menstrual cycles, you will have a urine or blood (less than 1
teaspoon) pregnancy test every week for the first 4 weeks, then every 2 weeks while taking
lenalidomide, again as soon as you stop taking lenalidomide, and then at 14 days and 28 days
after you have stopped taking lenalidomide.
Length of Treatment:
You may receive rituximab for up to 12 cycles. You may continue taking lenalidomide for as
long as the doctor thinks it is in your best interest. You will no longer be able to take
the study drugs if the disease gets worse, if intolerable side effects occur, or if you are
unable to follow study directions.
Your participation on the study will be over once you have completed your last study drug
dose (if you are male) or your last follow-up pregnancy test (if you are female).
This is an investigational study. Lenalidomide and rituximab are FDA approved and
commercially available. Lenalidomide is approved for the treatment of multiple myeloma and
some myelodysplastic syndromes. Rituximab is approved for the treatment of CLL. The
combination of these drugs to treat CLL is investigational.
Up to 120 patients will take part in this study. All will be enrolled at M. D. Anderson.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate
Participants evaluated for response by 2008 International Workshop on Chronic Lymphocytic Leukemia [IWCLL] overall response criteria by 6 months of treatment. Bone marrow biopsy and aspiration to check the status of the disease. Responses assessed after 3, 6 and 12 cycles.
Alessandra Ferrajoli, MD,BS
UT MD Anderson Cancer Center
United States: Institutional Review Board
|UT MD Anderson Cancer Center||Houston, Texas 77030|